AU2019241300B2 - Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade - Google Patents

Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade Download PDF

Info

Publication number
AU2019241300B2
AU2019241300B2 AU2019241300A AU2019241300A AU2019241300B2 AU 2019241300 B2 AU2019241300 B2 AU 2019241300B2 AU 2019241300 A AU2019241300 A AU 2019241300A AU 2019241300 A AU2019241300 A AU 2019241300A AU 2019241300 B2 AU2019241300 B2 AU 2019241300B2
Authority
AU
Australia
Prior art keywords
chromatography
purified
filtrate
purification
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019241300A
Other languages
English (en)
Other versions
AU2019241300A1 (en
Inventor
Yi Hong
Fei Wang
Ting YAN
Jiangguo YING
Haojie Zhang
Li Zhang
Luyi ZHANG
Dijun ZHAO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abelzeta Inc
Original Assignee
Abelzeta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abelzeta Inc filed Critical Abelzeta Inc
Publication of AU2019241300A1 publication Critical patent/AU2019241300A1/en
Assigned to CELLULAR BIOMEDICINE GROUP, INC. reassignment CELLULAR BIOMEDICINE GROUP, INC. Request for Assignment Assignors: CELLULAR BIOMEDICINE GROUP HK LIMITED
Assigned to AbelZeta Inc. reassignment AbelZeta Inc. Amend patent request/document other than specification (104) Assignors: CELLULAR BIOMEDICINE GROUP, INC.
Application granted granted Critical
Publication of AU2019241300B2 publication Critical patent/AU2019241300B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3847—Multimodal interactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/02—Separating microorganisms from the culture medium; Concentration of biomass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1017—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by filtration, e.g. using filters, frits, membranes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/04—Preparation or injection of sample to be analysed
    • G01N30/06—Preparation

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Sustainable Development (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AU2019241300A 2018-03-28 2019-03-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade Active AU2019241300B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810264813.X 2018-03-28
CN201810264813.XA CN110317832B (zh) 2018-03-28 2018-03-28 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法
PCT/CN2019/080213 WO2019184995A1 (zh) 2018-03-28 2019-03-28 Gmp级规模化制备重组慢病毒载体的纯化制剂的方法

Publications (2)

Publication Number Publication Date
AU2019241300A1 AU2019241300A1 (en) 2020-10-22
AU2019241300B2 true AU2019241300B2 (en) 2025-03-27

Family

ID=68058553

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019241300A Active AU2019241300B2 (en) 2018-03-28 2019-03-28 Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade

Country Status (8)

Country Link
US (3) US12018293B2 (https=)
EP (1) EP3778905A4 (https=)
JP (2) JP7837674B2 (https=)
KR (1) KR20200136448A (https=)
CN (1) CN110317832B (https=)
AU (1) AU2019241300B2 (https=)
SG (1) SG11202009824WA (https=)
WO (1) WO2019184995A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110317791A (zh) 2018-03-29 2019-10-11 西比曼生物科技（香港）有限公司 Gmp级无血清悬浮细胞大规模生产慢病毒的方法
CN110714029B (zh) * 2019-11-06 2024-08-16 无锡生基医药科技有限公司 一种慢病毒载体全封闭生产的方法及系统
CN111876393A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产高纯度高活性慢病毒载体的方法
CN111876392A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产病毒载体的方法
CN114181970B (zh) * 2020-09-15 2023-07-25 上海药明巨诺生物医药研发有限公司 一种慢病毒载体纯化方法
CN113373120B (zh) * 2021-06-18 2022-04-26 浙江康佰裕生物科技有限公司 Gmp级逆转录病毒载体的纯化方法与应用
CN113667596A (zh) * 2021-08-20 2021-11-19 上海药明生基医药科技有限公司 一种用于慢病毒载体制备的低温混匀装置和慢病毒载体的纯化方法
CN116121208A (zh) * 2023-01-31 2023-05-16 金宇保灵生物药品有限公司 牛轮状病毒纯化浓缩方法及牛轮状病毒浓缩液
CN116769736B (zh) * 2023-08-17 2023-11-14 赛奥斯博生物科技(北京)有限公司 一种快速纯化慢病毒的生产工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175906A1 (en) * 2007-12-21 2009-07-09 Wyeth Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760633B2 (en) 1998-08-14 2003-05-22 Merck Sharp & Dohme Corp. Process for purifying human papillomavirus virus-like particles
AU2002348151A1 (en) 2001-11-05 2003-05-19 Genvec, Inc. Viral vector production methods and compositions
US20030175688A1 (en) * 2002-03-15 2003-09-18 Rukmini Pennathur-Das Method for the purification and production of oncolytic adenoviruses
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
WO2007095336A2 (en) * 2006-02-15 2007-08-23 The Immune Response Corporation Production of hiv
PL2007883T3 (pl) * 2006-04-20 2012-07-31 Wyeth Llc Sposób oczyszczania do izolacji oczyszczonego wirusa pęcherzykowatego zapalenia jamy ustnej z hodowli komórkowej
CN102203242B (zh) * 2008-11-03 2013-06-12 克鲁塞尔荷兰公司 产生腺病毒载体的方法
CN101993472A (zh) * 2009-08-19 2011-03-30 中国科学院上海生命科学研究院 一种微型多用途生物大分子分离纯化装置
CN202226858U (zh) * 2011-09-21 2012-05-23 扬州优邦生物制药有限公司 一种病毒液纯化、浓缩装置
PT2782997T (pt) 2011-11-24 2018-04-09 Genethon Sistema de produção de vetor lentiviral escalável compatível com aplicações farmacêuticas industriais
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
RU2709678C2 (ru) * 2013-03-15 2019-12-19 Дзе Чилдрен'З Хоспитал Оф Филадельфия Масштабный производственный способ получения рекомбинантных лентивирусных векторов в системе культивирования клеток в бессывороточной суспензии
CN103642760B (zh) * 2013-11-14 2016-08-17 北京万泰生物药业股份有限公司 一种制备柯萨奇a16型病毒完整实心颗粒的方法
CN103881984A (zh) 2013-12-06 2014-06-25 深圳市赛百诺基因技术有限公司 无血清悬浮细胞生产重组腺病毒的方法及其药品制剂生产方法
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
CN104371982A (zh) * 2014-10-21 2015-02-25 武汉维诺赛生物技术有限公司 一种慢病毒的纯化方法
MX2017010217A (es) * 2015-02-09 2017-11-10 Univercells Nv Sistema, aparato y metodo para la produccion de celulas y/o productos de celulas.
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
CN105420202A (zh) * 2015-12-30 2016-03-23 苏州药明康德检测检验有限责任公司 病毒纯化放大方法
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
CN107523555A (zh) 2016-06-22 2017-12-29 武汉光谷人福生物医药有限公司 获得病毒的方法
CN107841482B (zh) 2016-09-21 2021-07-27 上海倍谙基生物科技有限公司 Mdck细胞无血清悬浮培养技术生产h9亚型流感疫苗
CN106434571A (zh) 2016-10-19 2017-02-22 深圳源兴基因技术有限公司 一种wave无血清培养悬浮细胞制备重组腺病毒的方法
CN106474466B (zh) * 2016-12-07 2018-04-13 申联生物医药（上海）股份有限公司 一种口蹄疫疫苗的制备方法
CN206635330U (zh) * 2017-03-23 2017-11-14 上海海利生物技术股份有限公司 一种病毒颗粒抗原纯化浓缩设备
CN107384877B (zh) * 2017-08-18 2020-09-08 深圳源兴基因技术有限公司 一种慢病毒的纯化方法
CN107630037A (zh) * 2017-10-19 2018-01-26 和元生物技术（上海）股份有限公司 一种获得高纯度腺相关病毒载体的纯化工艺

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175906A1 (en) * 2007-12-21 2009-07-09 Wyeth Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof

Also Published As

Publication number Publication date
JP2021518757A (ja) 2021-08-05
US12018293B2 (en) 2024-06-25
EP3778905A4 (en) 2021-12-22
CN110317832B (zh) 2022-07-05
CN110317832A (zh) 2019-10-11
KR20200136448A (ko) 2020-12-07
US20210147826A1 (en) 2021-05-20
JP2024041758A (ja) 2024-03-27
US20210009966A1 (en) 2021-01-14
EP3778905A1 (en) 2021-02-17
JP7837674B2 (ja) 2026-03-31
SG11202009824WA (en) 2020-11-27
AU2019241300A1 (en) 2020-10-22
US12577541B2 (en) 2026-03-17
US20240309337A1 (en) 2024-09-19
WO2019184995A1 (zh) 2019-10-03

Similar Documents

Publication Publication Date Title
AU2019241300B2 (en) Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade
Kuiper et al. Purification of a functional gene therapy vector derived from Moloney murine leukaemia virus using membrane filtration and ceramic hydroxyapatite chromatography
Slepushkin et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or Mustang Q ion exchange capsule
AU2019241301B2 (en) Method for large-scale production of lentivirus by using GMP-level serum-free suspension cells
JP6212039B2 (ja) 真核細胞の形質導入に有用なウイルスベースのベクター組成物
Boroujeni et al. The superiority of sucrose cushion centrifugation to ultrafiltration and PEGylation in generating high-titer lentivirus particles and transducing stem cells with enhanced efficiency
CN108118070A (zh) 一种慢病毒制备方法
US11993782B2 (en) Lentivirus packaging system, lentivirus produced by the same, cell transduced by the lentivirus, method for improving lentivirus production in a host cell, and method of using the cell for treating cancer
US20240279681A1 (en) Method for purification of gmp-grade retroviral vector and application thereof
US20240271107A1 (en) Vector manufacturing processes
US20230304037A1 (en) Methods for producing clinical-grade lentiviral vector
HK40045132A (en) Method for large-scale preparation of purified preparation of recombinant lentiviral vector at gmp grade
JPWO2019184995A5 (https=)
CN119256087A (zh) 慢病毒制造平台
CN107043785B (zh) 一种整合型慢病毒载体表达系统
JP2025520432A (ja) エンベロープ型ウイルスを産生する方法
CN117025684B (zh) 包含阳离子层析的慢病毒载体纯化方法
CN119592631A (zh) 一种符合iit临床质检标准的慢病毒快速包装方法及应用
CN119020417A (zh) 逆转录病毒载体的批量化生产方法、及其载体和用途
CN116656616A (zh) 一种制备外泌体的方法及其应用
HK40042109A (en) Method for large-scale production of lentivirus by using gmp-level serum-free suspension cells
WO2012126369A1 (zh) 核苷酸、包括其的重组载体、细胞、组合物及它们的应用

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELLULAR BIOMEDICINE GROUP, INC.

Free format text: FORMER APPLICANT(S): CELLULAR BIOMEDICINE GROUP HK LIMITED

HB Alteration of name in register

Owner name: ABELZETA INC.

Free format text: FORMER NAME(S): CELLULAR BIOMEDICINE GROUP, INC.

FGA Letters patent sealed or granted (standard patent)